# Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

> **NCT06343792** · PHASE2 · RECRUITING · sponsor: **ReAlta Life Sciences, Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Steroid Refractory GVHD

## Interventions

- **DRUG:** RLS-0071

## Key facts

- **NCT ID:** NCT06343792
- **Lead sponsor:** ReAlta Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343792, "Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06343792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*